Literature DB >> 35861541

Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.

Deiziane V S Costa1,2, Natalie V S Pham3, Rachel A Hays4, David T Bolick1, Sophia M Goldbeck3, Melinda D Poulter5, Sook C Hoang6, Jae H Shin1, Martin Wu7, Cirle A Warren1.   

Abstract

Clostridioides difficile infection (CDI) is the fifth leading cause of death from nonmalignant gastrointestinal disease in the United States. The contribution of resistance to C. difficile-active antibiotics to the outcomes of CDI is unclear. We evaluated the antimicrobial susceptibility of C. difficile isolates in a U.S. hospital and determined associations of clinical variables and binary toxin positivity with antibiotic resistance. C. difficile spores were cultured from fecal specimens of adult patients with CDI for genotyping and antimicrobial susceptibility assay (for clindamycin [CLI], fidaxomicin [FDX], metronidazole [MTZ], moxifloxacin [MXF], tigecycline [TGC], and vancomycin [VAN]). Electronic medical records were reviewed for clinical data extraction. Ninety-seven of 130 (75%) fecal samples grew toxigenic C. difficile in culture. Most of the isolates were tcdA+ tcdB+ cdtB- (80.4%), and 18.6% and 1% were tcdA+ tcdB+ cdtB+ and tcdA- tcdB+ cdtB+, respectively. Susceptibility to VAN, MTZ, FDX, TGC, MXF, and CLI was 96%, 94%, 100%, 100%, 8%, and 79%, respectively. Six isolates, all cdtB positive and belonging to the 027 ribotype, were resistant to VAN and/or MTZ. Higher MICs were found in isolates with a mutation in the VAN-related resistance gene vanR, but not vanS. In addition, cdtB+ isolates exhibited higher MICs of VAN, MTZ, TGC, CLI, and MXF compared to cdtB- strains. Patients with greater intestinal inflammation or severe disease were more likely to be infected with cdtB+ strains. Decreased susceptibility to antibiotics is not directly associated with either severe or recurrent CDI. However, antimicrobial susceptibility of C. difficile is decreased in strains positive for the binary toxin gene.

Entities:  

Keywords:  Clostridioides difficile; antibiotic resistance; binary toxin; fidaxomicin; metronidazole; tigecycline; vancomycin

Mesh:

Substances:

Year:  2022        PMID: 35861541      PMCID: PMC9380565          DOI: 10.1128/aac.00489-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  45 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013.

Authors:  Sofie M van Dorp; Pete Kinross; Petra Gastmeier; Michael Behnke; Axel Kola; Michel Delmée; Anastasia Pavelkovich; Silja Mentula; Frédéric Barbut; Agnes Hajdu; André Ingebretsen; Hanna Pituch; Ioana S Macovei; Milica Jovanović; Camilla Wiuff; Daniela Schmid; Katharina Ep Olsen; Mark H Wilcox; Carl Suetens; Ed J Kuijper
Journal:  Euro Surveill       Date:  2016-07-21

3.  Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile.

Authors:  Warren N Fawley; C W Knetsch; Duncan R MacCannell; Celine Harmanus; Tim Du; Michael R Mulvey; Ashley Paulick; Lydia Anderson; E J Kuijper; Mark H Wilcox
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

4.  Antibiotic Resistance and Toxin Production of Clostridium difficile Isolates from the Hospitalized Patients in a Large Hospital in Florida.

Authors:  Zhong Peng; Anteneh Addisu; Sally Alrabaa; Xingmin Sun
Journal:  Front Microbiol       Date:  2017-12-22       Impact factor: 5.640

5.  Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.

Authors:  Jane Freeman; Jonathan Vernon; Sally Pilling; Kirsti Morris; Scott Nicolson; Sharie Shearman; Emma Clark; Jose Alejandro Palacios-Fabrega; Mark Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-07       Impact factor: 3.267

Review 6.  Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.

Authors:  Sajad Yaghoubi; Angelina Olegovna Zekiy; Marcela Krutova; Mehrdad Gholami; Ebrahim Kouhsari; Mohammad Sholeh; Zahra Ghafouri; Farajolah Maleki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-05       Impact factor: 3.267

Review 7.  Regulation of Resistance in Vancomycin-Resistant Enterococci: The VanRS Two-Component System.

Authors:  Alexandra A Guffey; Patrick J Loll
Journal:  Microorganisms       Date:  2021-09-25

8.  Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.

Authors:  Adam Cheknis; Dominique Devaris; Laurent Chesnel; Suzanne E Dale; Julia Nary; Susan P Sambol; Diane M Citron; Richard V Goering; Stuart Johnson
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

Review 9.  The prognostic value of toxin B and binary toxin in Clostridioides difficile infection.

Authors:  Salvador López-Cárdenas; Eva Torres-Martos; Juan Mora-Delgado; Juan Manuel Sánchez-Calvo; Marta Santos-Peña; Ángel Zapata López; María Dolores López-Prieto; Salvador Pérez-Cortés; Juan Carlos Alados
Journal:  Gut Microbes       Date:  2021-03-04

10.  High Prevalence of Multidrug-Resistant Clostridioides difficile Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya.

Authors:  Winnie C Mutai; Marianne W Mureithi; Omu Anzala; Gunturu Revathi; Brian Kullin; Magdaline Burugu; Cecilia Kyany'a; Erick Odoyo; Peter Otieno; Lillian Musila
Journal:  Front Cell Infect Microbiol       Date:  2021-02-08       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.